NEW YORK – Generex Biotechnology, a biopharma and diagnostics firm based in Miramar, Florida, today said that it has signed a letter of intent to acquire immunotherapy firm Kiromic.

Generex said that it intends to merge Kiromic with a newly formed entity, called NuGenerex Immuno-Oncology, that will contain the operations of both Kiromic and Generex subsidiary Antigen Express, which is developing AE37, an experimental cancer vaccine, in combination with checkpoint inhibitors for treatment of triple negative breast cancer.